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Summary
Background Cancer survival is a key measure of the eﬀ ectiveness of health-care systems. Persistent regional and 
international diﬀ erences in survival represent many avoidable deaths. Diﬀ erences in survival have prompted or 
guided cancer control strategies. This is the ﬁ rst study in a programme to investigate international survival disparities, 
with the aim of informing health policy to raise standards and reduce inequalities in survival.
Methods Data from population-based cancer registries in 12 jurisdictions in six countries were provided for 2·4 million 
adults diagnosed with primary colorectal, lung, breast (women), or ovarian cancer during 1995–2007, with follow-up 
to Dec 31, 2007. Data quality control and analyses were done centrally with a common protocol, overseen by external 
experts. We estimated 1-year and 5-year relative survival, constructing 252 complete life tables to control for background 
mortality by age, sex, and calendar year. We report age-speciﬁ c and age-standardised relative survival at 1 and 5 years, 
and 5-year survival conditional on survival to the ﬁ rst anniversary of diagnosis. We also examined incidence and 
mortality trends during 1985–2005.
Findings Relative survival improved during 1995–2007 for all four cancers in all jurisdictions. Survival was persistently 
higher in Australia, Canada, and Sweden, intermediate in Norway, and lower in Denmark, England, Northern Ireland, 
and Wales, particularly in the ﬁ rst year after diagnosis and for patients aged 65 years and older. International 
diﬀ erences narrowed at all ages for breast cancer, from about 9% to 5% at 1 year and from about 14% to 8% at 5 years, 
but less or not at all for the other cancers. For colorectal cancer, the international range narrowed only for patients 
aged 65 years and older, by 2–6% at 1 year and by 2–3% at 5 years. 
Interpretation Up-to-date survival trends show increases but persistent diﬀ erences between countries. Trends in 
cancer incidence and mortality are broadly consistent with these trends in survival. Data quality and changes in 
classiﬁ cation are not likely explanations. The patterns are consistent with later diagnosis or diﬀ erences in treatment, 
particularly in Denmark and the UK, and in patients aged 65 years and older. 
Funding Department of Health, England; and Cancer Research UK.
Introduction
Survival is a key index of the overall eﬀ ectiveness of health 
services in the management of patients with cancer. 
Substantial diﬀ erences in survival have been reported for 
adult patients with cancer who were diagnosed in many 
countries in the early 1990s (CONCORD)1 and in Europe 
up to 2002 (EUROCARE).2 Survival has improved, but 
substantial diﬀ erences still exist within and between 
countries with similar health systems and wealth, such as 
between Denmark and the UK and other European 
countries.2–5 Findings from one study suggest that for 
patients diagnosed up to 1999, about 11 400 more patients 
with cancer died per year within 5 years of diagnosis in 
England, Scotland, and Wales than if 5-year survival had 
been as high as the highest levels achieved in 13 other 
countries in Europe;6 cancers of the breast, colorectum, 
and lung accounted for about half the avoidable deaths. 
Avoidable deaths also arise from inequalities in survival 
within countries; even in Finland, with some of the highest 
survival levels in Europe, 4–7% of cancer deaths have been 
attributed to inequalities in 5-year survival between 
educational groups.7 However, the CONCORD and 
EUROCARE studies relate to patients diagnosed at least 
8 years ago, and many countries have implemented cancer 
control plans since then.
Survival patterns help to drive national cancer strategies 
(references in webappendix p 2). In Denmark, the ﬁ rst 
National Cancer Plan (2000) focused on the survival deﬁ cit 
with neighbouring countries. The second plan (2005) also 
noted poorer survival than in other Nordic countries, 
especially just after diagnosis; it recommended reduction 
of diagnostic delay and establishment of multidisciplinary 
cancer groups. The Northern Ireland cancer plan (1996) 
introduced centres of excellence and multidisciplinary 
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teams. The National Health Service Cancer Plan for 
England (2000) focused on improving cancer services and 
raising 5-year survival to the levels of the best-performing 
countries in Europe by 2010; the updated strategy (2007) 
also aims to raise cancer survival to the levels of the best. 
The 10-year strategy in Wales (2006) aims to achieve levels 
of survival within the top European quartile by 2015. In 
Australia, improving cancer services to raise survival has 
been a key platform of both cancer plans in New South 
Wales (2004–10), and the cancer action plan in 
Victoria (2008) aims “to increase survival rates by 10% 
by 2015, saving 2000 lives”.8 Norway’s ﬁ rst national cancer 
plan (1999) aimed to improve cancer care; the updated 
strategy (2006) introduced oﬃ  cial treatment guidelines. 
Canada created the independent non-proﬁ t Canadian 
Partnership Against Cancer to implement its cancer 
control strategy from 2007. A national cancer strategy for 
Sweden was proposed in 2009; two of the ﬁ ve goals are to 
improve survival and quality of life for patients with 
cancer, and to reduce regional diﬀ erences in survival. One 
goal of the World Cancer Declaration9 is to achieve major 
improvements in survival worldwide by 2020.
Survival trends are also being used to assess cancer 
strategies. Denmark, Norway, and England introduced 
cancer plans in 1999–2000. Trends in short-term survival 
up to 2006 have suggested some beneﬁ t in Denmark, 
mainly for surgically treated cancers,10 but overall 
assessment of the cancer plans in Denmark and Norway 
suggests they have yet to show a distinct eﬀ ect on survival 
trends.11 Survival was already improving in England by 2000, 
but evidence suggests some acceleration in the trend during 
2004–07, after full implementation of the cancer plan.12
For any country, policy designed to achieve levels of 
cancer survival comparable with an external standard 
requires robust and timely evidence of the extent and 
causes of any current deﬁ cit. The International Cancer 
Benchmarking Partnership (ICBP) was designed for 
this purpose. It brings together epidemiologists, 
clinicians, other scientists, and policy makers from six 
countries. Countries were invited to participate on the 
basis of comparable wealth, universal access to health 
care, and longstanding, high-quality, population-based 
cancer registration. The aims of the ICBP are to produce 
up-to-date survival estimates for selected cancers, to 
establish whether international diﬀ erences in survival 
have changed, and to investigate the causes of survival 
deﬁ cits. The goal is to provide policy makers with high-
quality evidence on which they can take action. This 
ﬁ rst report is focused on survival trends.
Methods
Study design and data collection
Four index cancers were selected. Cancers of the breast, 
colorectum, and lung are common, whereas ovarian 
cancer is less common and has a complex diagnostic 
pathway. Data were provided from population-based 
cancer registries in 12 jurisdictions in six countries: 
Australia (New South Wales, Victoria), Canada (Alberta, 
British Columbia, Manitoba, Ontario), Denmark, Norway, 
Sweden (Uppsala-Örebro and Stockholm-Gotland health 
regions), and the UK (England, Northern Ireland, and 
Wales). Data for Denmark, Norway, England, Northern 
Ireland, and Wales covered the national population. 
Population coverage was for selected regions of 
Austra lia (11·4 million of 19·2 million; 59·7%), Canada 
(19·9 million of 31·0 million; 64·9%), and Sweden 
(3·8 million of 8·9 million; 42·8%), but the quality and 
completeness of all the registries is known to be high.13 
In 2002, the six countries had a combined population of 
122·9 million, of which 98·9 million (80·5%) were 
covered by the data contributed for this study.
Anonymised, individual cancer registration records were 
supplied for adults (aged 15–99 years) diagnosed with a 
primary, invasive, malignant neoplasm of the colorectum, 
lung, breast (women only), or ovary during the 13 years 
from 1995 to 2007, with follow-up to Dec 31, 2007. Data for 
ovarian cancer were not available for Sweden. Data were 
requested for in-situ and other non-invasive tumours to 
enable comparison of diagnostic intensity in the 
participating jurisdictions, but not all registries were able 
to provide complete data for these tumours. Datasets were 
received between April 12 and Aug 10, 2010.
Data were supplied with the anatomical location of 
tumours coded to the tenth revision of the International 
Classiﬁ cation of Diseases (ICD-10)14 or the third revision of 
the International Classiﬁ cation of Diseases for Oncology 
(ICD-O-3).15 Cancers were selected on the basis of these 
codes: colon (ICD-10 C18.0-C18.9), rectosigmoid junction 
(C19; ICD-O-3 C19.9), and rectum (C20; ICD-O-3 C20.9) 
excluding anus and anal canal (ICD-10 C21); lung and 
bronchus (C34.0-C34.9) excluding trachea (C33); breast 
(C50.0-C50.9); and ovary including the fallopian tube and 
adnexa (C56 [ICD-O-3 C56.9]; C57.0-C57.9). Tumour 
morphology and behaviour were coded to ICD-O-216 or 
ICD-O-3.
Data were provided for date of diagnosis, anatomical 
site, morphology and behaviour of the tumour, and date 
of birth, sex, and last known vital status of the patient. 
The New South Wales registry does not collect full dates 
(day, month, year) of birth or diagnosis, and Denmark 
only collected the full date of diagnosis from 2004. This 
limitation disabled some of the quality control checks 
and counts of deaths within 30 days of diagnosis. It also 
reduced the comparability of very short-term survival 
estimates.17 Four registries collect full dates but could 
not provide them for this study; they provided the 
duration of survival in days. Data were also provided on 
diagnostic investigations, stage at diagnosis and 
treatment, and availability of health-care resources such 
as specialist oncologists or imaging technology. These 
data will be the subject of further analyses.
National incidence and mortality rates for 1998–2002 
were derived from CI5plus18 and from the WHO mortality 
databank.19 Trends in the 3-year moving average 
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world-standardised yearly incidence and mortality rates 
per 100 000 population for the six countries over the 
period 1985–2005 were derived from the same databases 
and from several other oﬃ  cial sources.
Data were transmitted via the secure web-based 
delivery system HyperSend, which meets the security 
standards for electronic transmission of health data 
under the US Health Insurance Portability and 
Accountability Act (PL104-191, 1996). Each ﬁ le was 
encrypted and sent in a separate transmission, itself also 
encrypted. Passwords were obtained separately from 
pre-assigned contact persons in each registry. A few 
registries submitted password-protected encrypted ﬁ les 
on unlabelled CDROMs via courier. Files were named 
with pre-assigned random codes; variable names were 
sequential, rather than informative. No primary 
identifying data (name, address, postcode, etc) were 
included in any ﬁ le. For quality control purposes, each 
tumour record included a unique serial number assigned 
by the source registry to enable the record to be checked 
if errors were detected.
The London School of Hygiene and Tropical Medicine 
(LSHTM) is registered (number Z7513362) in the UK 
under the Data Protection Act 1998. The study protocol 
and the Cancer Research UK Cancer Survival Group’s 
system-level security policy at LSHTM were approved for 
processing sensitive patient data without consent for this 
study by the Ethics and Conﬁ dentiality Committee of the 
statutory National Information Governance Board 
(NIGB) on April 21, 2010 (extension of PIAG 1-05(c)2007). 
The NIGB noted that “it would be necessary to have full 
dates of birth, diagnosis and death, as survival calculation 
required precise dates”. The study protocol was also 
approved by the South East Research Ethics Committee 
of the National Health Service on April 21, 2010 
(10/H1102/19). Participating registries outside the UK 
obtained ethical approvals in their jurisdictions (details 
available on request).
Quality control
Each dataset was examined for adherence to protocol and 
the distribution of key variables. Results were discussed 
with each registry and any corrections agreed. In many 
cases, revised datasets were submitted. All tumour records 
were then subjected to standardised quality control 
procedures.1 The results were again discussed with 
participating registries; data preparation routines were 
adjusted when necessary to take account of local coding 
practices. We excluded the records of 102 305 patients 
Figure 1: Structure of cohort and period approaches to survival analysis for patients diagnosed during 1995–2007 and followed up to Dec 31, 2007
*Calendar years from which the probabilities of conditional survival in each follow-up interval are combined to produce cumulative survival estimates. Numbers in 
the cells indicate the minimum number of years of follow-up completed by patients surviving to the end of a speciﬁ c calendar year (columns) who were diagnosed in 
the index year (rows). Cohort approach: all patients diagnosed in a speciﬁ c period were followed up for at least 5 years (full lines). Period approach: survival estimates 
from most recent follow-up data (shaded orange).
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Calendar years of follow-up*
 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 
1995 0 1 2 3 4 5 6 7 8 9 10 11 12 1995
1996  0 1 2 3 4 5 6 7 8 9 10 11 1996
1997   0 1 2 3 4 5 6 7 8 9 10 1997
1998    0 1 2 3 4 5 6 7 8 9 1998
1999     0 1 2 3 4 5 6 7 8 1999
2000      0 1 2 3 4 5 6 7 2000
2001       0 1 2 3 4 5 6 2001
2002        0 1 2 3 4 5 2002
2003         0 1 2 3 4 2003
2004          0 1 2 3 2004
2005           0 1 2 2005
2006            0 1 2006
2007             0 2007
Data used in cohort analysis
Data used in period analysis
Eligible for analysis Excluded Included in analyses
DCO* Multiple 
same site†
Other‡
Australian registries
New South Wales 145 174 1·0% 0·0% 0·2% 143 537 (98·9%)
Victoria 110 844 1·8% 0·0% 0·3% 108 551 (97·9%)
Canadian registries
Alberta 61 046 0·2% 1·2% 0·2% 60 003 (98·3%)
British Columbia 97 762 1·4% 0·0% 0·6% 95 829 (98·0%)
Manitoba 28 752 1·2% 0·0% 0·3% 28 327 (98·5%)
Ontario 285 803 1·7% 0·0% 0·0% 280 892 (98·3%)
Denmark 153 442 0·5% 0·5% 1·2% 150 108 (97·8%)
Norway 111 314 0·8% 1·3% 0·5% 108 452 (97·4%)
Swedish regions§ 71 321 0·0% 1·0% 0·0% 70 554 (98·9%)
UK registries
England 1 312 523 4·4% 0·6% 1·0% 1 234 029 (94·0%)
Northern Ireland 38 863 1·3% 0·3% 0·6% 38 007 (97·8%)
Wales 87 897 4·7% 0·2% 0·1% 83 455 (94·9%)
Total 2 504 741 2·9% 0·5% 0·7% 2 401 744 (95·9%)
Data show number and percentage of patients eligible, excluded, and included in analyses, by jurisdiction. 
*Registration from a death certiﬁ cate only (DCO). †Multiple tumours at same anatomical site. ‡Aged 100 years or older 
at diagnosis, sex or last vital status unknown, autopsy only, sex-site error, invalid dates, or duplicate registration. 
§Autopsy-only cases not provided.
Table 1: Adults (15–99 years) diagnosed with colorectal, lung, breast (women), or ovarian cancer 
between 1995 and 2007 and followed up to Dec 31, 2007
For more on HyperSend see 
http://www.hypersend.com
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whose tumour was benign (behaviour code 0), of uncertain 
or borderline malignancy (1), in-situ (2), or metastatic to 
the index organ from elsewhere (6). Most exclusions were 
for women with an in-situ neoplasm of the breast 
(52 705 patients, 5·8% of all 916 179 breast tumours 
reported) or an ovarian neoplasm of uncertain or 
borderline malignancy (10 409, 7·6% of all 137 199 ovarian 
neoplasms reported; webappendix pp 6–9).
Of the 2 504 741 adults eligible for analysis with an 
invasive, primary, malignant neoplasm of the colorectum, 
lung, breast, or ovary diagnosed during 1995–2007, we 
excluded a further 102 997 (4·1%). We excluded 
registrations made from a death certiﬁ cate only (DCO) 
from survival analyses because the date of diagnosis and 
thus the duration of survival were unknown. 
They accounted for 73 603 (2·9%) of eligible cases: 
2·4% (18 269/759 097) for colorectal cancer, 5·1% 
(38 561/758 792) for lung cancer, 1·5% (12 592/860 971) 
for breast cancer, and 3·3% (4181/125 881) for ovarian 
cancer. We excluded a further 3208 patients (0·13% of 
those eligible) because their vital status at Dec 31, 2007, 
was unknown, and 26 186 (1·0%) because of unknown 
sex, age 100 years or older at diagnosis, invalid dates or 
sequence of dates, diagnosis made only at autopsy, or a 
previous primary cancer at the same anatomical site.
Overall, data quality was high. The proportion of 
patients included in the analyses varied very little during 
1995–2007. The lowest proportion for any period 
was 92·6% (104 858/113 181) for lung cancer in 1995–96 
(details of exclusions by jurisdiction and calendar period 
available on request). For patients diagnosed during 
2000–07, morphological veriﬁ cation of the primary can-
cer diagnosis was available for 91·4% (428 464/468 986) 
of colorectal cancers, 75·1% (339 053/451 329) of lung 
cancers, 94·4% (506 225/536 257) of breast cancers, 
and 84·5% (64 262/76 011) of ovarian cancers.
All patients with a qualifying index cancer were 
included in the analyses, irrespective of whether it 
was their ﬁ rst, second, or higher-order cancer 
(webappendix p 19). Inclusion of all primary cancers in 
survival estimates is important for public health because 
the number of people who develop a second cancer will 
continue to rise with ageing populations and 
improvements in survival. To the extent that second 
tumours confer shorter survival than ﬁ rst tumours, 
inclusion of all primary cancers also reduces any bias in 
Australia Canada Denmark Norway Swedish 
regions
UK
Australian 
registries
New South 
Wales
Victoria Canadian 
registries
Alberta British 
Columbia
Manitoba Ontario UK 
registries
England Northern 
Ireland
Wales
Colorectal cancer
1 year
1995–99 80·0% 80·3% 79·6% 79·1% 77·6% 80·7% 79·8% 78·7% 71·7% 78·6% 81·8% 70·2% 70·2% 74·3% 68·3%
2000–02 82·5% 83·2% 81·6% 81·5% 79·8% 82·4% 80·4% 81·7% 73·9% 78·7% 82·8% 73·0% 72·9% 76·8% 72·3%
2005–07 84·9% 84·7% 85·1% 83·5% 80·4% 84·3% 82·1% 83·9% 77·7% 82·4% 83·8% 74·7% 74·7% 76·2% 73·6%
5 years
1995–99 60·0% 61·2% 58·4% 58·1% 56·3% 59·8% 57·6% 58·0% 48·2% 56·9% 58·5% 47·8% 47·8% 51·1% 45·9%
2000–02 63·4% 65·1% 61·1% 60·9% 58·0% 61·5% 59·6% 61·3% 51·7% 58·8% 60·6% 51·3% 51·2% 54·3% 50·3%
2005–07 65·9% 66·4% 65·5% 63·7% 58·3% 64·0% 63·3% 64·9% 55·8% 62·0% 62·6% 53·6% 53·7% 55·2% 52·3%
Conditional 5-year
1995–99 75·0% 76·2% 73·4% 73·6% 72·5% 74·2% 72·2% 73·8% 67·3% 72·3% 71·6% 68·1% 68·2% 68·8% 67·2%
2000–02 76·7% 78·2% 74·9% 74·7% 72·5% 74·8% 74·0% 75·2% 70·1% 74·7% 73·3% 70·3% 70·3% 71·1% 69·7%
2005–07 77·7% 78·4% 76·8% 76·4% 72·3% 75·9% 77·1% 77·4% 72·1% 75·4% 74·8% 71·8% 71·8% 73·0% 71·1%
Lung cancer
1 year
1995–99 38·2% 38·6% 37·8% 38·7% 36·4% 36·6% 41·7% 39·6% 26·4% 32·3% 35·7% 24·3% 24·3% 27·4% 23·0%
2000–02 40·9% 41·5% 39·9% 39·7% 36·3% 37·5% 44·1% 40·5% 31·3% 32·2% 36·6% 27·5% 27·5% 28·3% 25·9%
2005–07 42·8% 42·9% 42·7% 43·1% 41·5% 43·0% 42·7% 43·4% 34·9% 39·2% 43·6% 29·7% 29·7% 30·6% 28·5%
5 years
1995–99 13·9% 14·2% 13·4% 15·7% 13·8% 13·9% 16·6% 16·6% 8·0% 11·0% 12·7% 7·0% 6·9% 9·7% 7·5%
2000–02 15·1% 16·2% 13·6% 15·9% 13·1% 14·0% 19·4% 16·7% 9·6% 11·0% 11·6% 8·1% 8·0% 9·7% 7·6%
2005–07 17·0% 17·6% 16·2% 18·4% 15·1% 17·7% 20·1% 19·1% 10·9% 14·4% 16·3% 8·8% 8·7% 11·0% 9·0%
Conditional 5-year
1995–99 35·1% 35·9% 34·0% 39·9% 37·0% 37·2% 39·5% 41·3% 28·6% 32·1% 35·1% 26·9% 26·6% 33·8% 29·2%
2000–02 36·0% 38·1% 33·0% 39·4% 35·6% 36·5% 44·2% 40·5% 29·4% 32·8% 31·5% 27·6% 27·4% 31·8% 27·7%
2005–07 38·6% 40·1% 36·6% 42·1% 35·4% 40·3% 47·4% 43·5% 30·3% 35·0% 36·5% 28·2% 27·9% 33·8% 30·2%
(Continues on next page)
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survival comparisons between recent and long- 
established registries. Newer registries are less likely to 
identify a second tumour correctly if the ﬁ rst tumour 
occurred years before the registry was established. With 
the exception of Northern Ireland (1993), however, all 
the registries in this study have been operating for 
decades, starting between 1942 (Denmark) and 1972 
(New South Wales). In this study, for example, a patient 
diagnosed with breast cancer in 1995 after a melanoma 
of the skin in 1990 would be included, but a patient 
with separate cancers of the same organ (eg, consecutive 
breast cancers) would be included in these analyses 
only for the ﬁ rst breast cancer, and only if that cancer 
was diagnosed during 1995–2007.
Statistical analysis
We estimated relative survival, which is the standard 
approach for population-based cancer survival.20 It is the 
ratio of the survival observed in patients with cancer and 
the survival that would have been expected if they had 
experienced only the all-cause death rates (background 
mortality) of the general population where they lived. 
Relative survival is interpretable as survival from the 
cancer after adjustment for other causes of death. It is 
required for international comparisons because it 
removes diﬀ erences in the survival of patients with 
cancer that are unrelated to their cancer. We estimated 
survival for each cancer in each jurisdiction; for Australia, 
Canada, and the UK, we also estimated survival with the 
pooled data from contributing registries.
Background mortality in the general population of each 
jurisdiction was taken from life tables of all-cause death 
rates by sex, single year of age, and calendar year during 
1995–2007. We constructed these tables from raw data on 
the numbers of deaths and the populations for selected 
years, by sex and single year of age or 5-year age group. 
The data were obtained from participating registries or 
vital statistics oﬃ  ces. Abridged (5-year) life tables were 
smoothed to complete (single-year-of-age) life tables and 
extended up to age 99 years with use of Poisson 
Australia Canada Denmark Norway Swedish 
regions
UK
Australian 
registries
New South 
Wales
Victoria Canadian 
registries
Alberta British 
Columbia
Manitoba Ontario UK 
registries
England Northern 
Ireland
Wales
(Continued from previous page)
Breast cancer (women)
1 year
1995–99 95·8% 95·8% 95·6% 95·9% 95·4% 97·1% 96·2% 95·5% 93·0% 95·4% 97·6% 90·4% 90·5% 92·6% 88·6%
2000–02 96·3% 96·5% 96·0% 96·2% 95·9% 96·5% 96·4% 96·0% 94·3% 95·8% 98·4% 92·4% 92·5% 95·0% 89·8%
2005–07 96·7% 96·5% 97·1% 96·3% 95·9% 97·1% 96·7% 96·1% 95·0% 96·6% 98·0% 94·2% 94·3% 95·0% 93·4%
5 years
1995–99 85·0% 85·5% 84·4% 85·3% 83·4% 87·1% 86·0% 84·9% 76·9% 81·8% 86·7% 74·8% 74·8% 77·5% 73·5%
2000–02 87·0% 87·4% 86·5% 86·4% 84·9% 87·5% 83·9% 86·6% 81·5% 83·8% 89·3% 78·8% 78·8% 81·6% 76·7%
2005–07 88·1% 87·8% 88·5% 86·3% 82·6% 89·1% 86·8% 86·4% 82·4% 85·5% 88·5% 81·6% 81·6% 84·1% 81·0%
Conditional 5-year
1995–99 88·8% 89·1% 88·2% 88·9% 87·3% 89·7% 89·4% 88·9% 82·6% 85·6% 88·8% 82·5% 82·4% 83·6% 82·7%
2000–02 90·3% 90·6% 90·0% 89·8% 88·5% 90·6% 87·0% 90·2% 86·4% 87·3% 90·6% 85·0% 85·0% 86·3% 85·1%
2005–07 91·0% 90·9% 91·2% 89·6% 86·0% 91·8% 89·7% 89·8% 86·6% 88·4% 90·2% 86·4% 86·4% 88·9% 86·4%
Ovarian cancer
1 year
1995–99 70·4% 70·4% 70·4% 71·8% 69·4% 74·0% 68·9% 71·9% 63·4% 70·4% ..  59·6% 59·8% 62·8% 56·6%
2000–02 71·1% 72·8% 68·9% 73·3% 71·0% 75·3% 74·1% 73·1% 67·9% 74·3% ..  62·4% 62·6% 64·9% 60·0%
2005–07 73·5% 73·3% 73·7% 75·2% 69·7% 77·6% 68·0% 75·9% 70·6% 75·2% ..  65·0% 65·4% 63·9% 60·5%
5 years
1995–99 36·1% 35·9% 36·4% 38·2% 41·4% 35·1% 32·7% 39·0% 31·5% 37·2% ..  32·6% 32·5% 39·0% 31·5%
2000–02 37·1% 39·6% 34·1% 38·4% 34·9% 37·8% 37·1% 39·1% 33·7% 40·2% ..  34·3% 34·3% 37·8% 33·8%
2005–07 37·5% 39·9% 34·2% 41·9% 36·9% 44·1% 28·8% 43·2% 36·1% 39·7% ..  36·4% 36·4% 36·5% 36·3%
Conditional 5-year
1995–99 48·8% 48·6% 49·2% 51·9% 58·3% 45·7% 43·7% 53·3% 48·9% 50·6% .. 53·1% 52·8% 63·0% 53·8%
2000–02 50·4% 53·0% 47·0% 50·9% 46·4% 49·1% 48·1% 52·2% 47·2% 52·2% ..  52·8% 52·6% 55·0% 53·9%
2005–07 48·7% 52·7% 43·5% 54·4% 50·8% 55·8% 39·1% 55·7% 48·8% 50·9% ..  53·8% 53·5% 55·7% 57·4%
Data are for period of diagnosis, cancer, and jurisdiction. Some age-standardised estimates arise from imputed age-speciﬁ c estimates. Estimates for conditional 5-year survival include only patients who survived 
at least 1 year after diagnosis. Analyses for 2005–07 are period estimates for patients diagnosed during 2005–07, or diagnosed earlier but alive on Jan 1, 2005. Ovarian cancer data were not supplied by Sweden.
Table 2: Age-standardised relative survival (%) at 1 and 5 years, and 5-year survival conditional on survival to the ﬁ rst anniversary of diagnosis
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regression, with ﬂ exible link functions to model the 
death rates. Life tables for each year were then produced 
by linear interpolation between period-speciﬁ c life tables. 
The most recent data on deaths were for 2005 or 2006, 
enabling construction of unique life tables for up to 11 of 
the 13 years during the period 1995–2007; 252 life tables 
were constructed to capture year-to-year changes in 
background mortality by age and sex in all jurisdictions.
All-cause and relative survival were estimated for adults 
of all ages combined at 1, 2, 3, 4, 5, 6, 9, and 12 months 
after diagnosis, then every 6 months to 5 years after 
diagnosis. We used the maximum likelihood approach to 
survival estimation with individual records,21 implemented 
in the open-source program strel22 with the statistical 
package Stata (version 11.1). Survival was estimated 
separately for the age groups 15–44, 45–54, 55–64, 65–74, 
and 75–99 years, but at wider intervals: 1, 2, 3, 4, 5, 6, 9, and 
12 months, then every 6 months to 3 years, then every 
year to 5 years after diagnosis. If survival could not be 
estimated for a speciﬁ c age group, we used the adjacent 
age-speciﬁ c estimate. Age-standardisation of relative 
survival was done with the international cancer survival 
standard weights.23
The cohort approach was used for 1995–99 and 
2000–02, since all patients diagnosed during these 
periods had at least 5 years’ potential follow-up by the 
end of 2007. The period approach24 was used to provide 
short-term predictions of 5-year survival for patients 
diagnosed during 2005–07. Period survival estimates 
combine the partial probabilities of survival up to each 
anniversary of diagnosis (here, up to 5 years) that were 
observed during the most recent period for which 
adequate follow-up data were available (in this report, 
the period 2005–07 for patients diagnosed during 
2000–07; shaded area in ﬁ gure 1). This approach mirrors 
the standard predictions of life expectancy at birth from 
the most recently recorded death rates at each age. Period 
survival estimates represent a prediction of the 5-year 
survival of patients diagnosed in 2005–07 under the 
assumption that the most recently observed partial 
probabilities of survival will remain constant throughout 
the follow-up period of interest (for these patients, up 
to 2012). In most cases they will rise, so the period 
estimates for 2005–07 are inherently conservative 
predictions of the (cohort) survival that will eventually be 
recorded when the data become available around 2014. 
Comparisons between jurisdictions are unbiased, since 
they are based on the same method for each 
calendar period.
We report age-standardised relative survival at 
1 year and 5 years after diagnosis. We also report relative 
survival at the ﬁ fth anniversary of diagnosis in patients 
who survived at least 1 year after their diagnosis. This 
conditional 5-year survival enables international 
comparisons while keeping to a minimum the eﬀ ect of 
factors that mainly aﬀ ect survival in the ﬁ rst year after 
diagnosis. Advice on study design, protocol, and 
methodology was provided by independent experts 
(Epidemiology Reference Group).
Role of the funding source
The Department of Health (London, UK) funded 
coordination and analysis, but had no role in preparing 
the protocol, or in collection, preparation, or analysis of 
the data. Cancer Research UK has funded the Cancer 
Survival Group at LSHTM (C1336/A5735 and A11700) 
since April, 2005, but had no role in study design, data 
collection, data analysis, data interpretation, or writing 
of the report. Neither funding source had any role in 
the decision to submit the report for publication. The 
corresponding author had full access to all the data and 
had ﬁ nal responsibility for the decision to submit 
for publication.
Results
2 401 744 adults diagnosed with one of the four index 
cancers during 1995–2007 were included in the analyses 
(95·9% of those eligible; table 1). The age proﬁ les of 
patients with each cancer were similar in all 
12 jurisdictions (webappendix pp 12–17).
The trends and geographical patterns in 1-year, 5-year, 
and conditional 5-year survival diﬀ ered between the 
four cancers, but some features were consistent. Survival 
rose in all six countries, for all four cancers (table 2, 
ﬁ gure 2). Survival was generally higher in Australia, 
Canada, and Sweden, intermediate in Norway, and lower 
in Denmark and the UK. Survival estimates for the three 
UK nations (England, Northern Ireland, and Wales) 
were mostly within 2–3% of each other. Survival in 
Alberta was often 3–5% lower than in the three other 
participating Canadian provinces. Webappendix pp 21–26 
shows relative survival by age, sex, jurisdiction, and 
calendar period.
Of 732 005 adults with a colorectal cancer diagnosed 
during 1995–2007, the mean age at diagnosis was 
70·9 years (range between the 12 jurisdictions 69·2–72·0; 
webappendix p 18). For 58 634 patients (8·0%, 
range 3·5–14·8), colorectal cancer was not their ﬁ rst 
cancer (webappendix p 19). Excluding New South Wales 
and Denmark, death within 1 month of diagnosis was 
reported for 57 648 of 629 693 patients (9·2%, 
range 4·2–11·0%; webappendix p 20).
Colorectal cancer survival increased at a similar pace in 
all six countries. The diﬀ erences in 1-year, 5-year, and 
conditional 5-year relative survival between Australia, 
Canada, Norway, and Sweden (higher-survival group) 
and Denmark and the UK (lower-survival group) persisted 
throughout 1995–2007 (table 2, ﬁ gure 2). Most of the 
diﬀ erences arose in the ﬁ rst year after diagnosis. The 
survival deﬁ cit in the UK and Denmark for 2005–07 
(period estimate), compared with Australia, Canada, and 
Sweden, was 8–10% at both 1 and 5 years. For patients 
aged 65 years and older, these diﬀ erences reached 10–15% 
(webappendix p 25).
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Of 715 330 patients with lung cancer, the mean age at 
diagnosis was 70·3 years (range 68·3–71·2; webappendix 
p 18). For 63 480 patients (8·9%, range 4·1–17·9), lung 
cancer was not their ﬁ rst cancer (webappendix p 19). 
Death within 1 month of diagnosis was reported for 
141 596 of 628 701 patients (22·5%, range 12·8–26·3; 
webappendix p 20).
Almost all the improvement in lung cancer survival is 
attributable to an increase in 1-year survival, for which 
the geographical diﬀ erences in survival were widest in 
1995–99 (table 2, ﬁ gure 2). For 2005–07, 1-year survival 
was around 30% in the UK nations, 35% in Denmark, 
and 39–44% in Australia, Canada, Norway, and Sweden. 
5-year survival was low at 9–11% in the UK and Denmark 
versus 15–20% in the other four countries. For 1995–99, 
5-year survival was highest in Manitoba, but diﬀ erences 
from other jurisdictions were small by 2005–07. The 
international range in conditional 5-year survival seems 
to have widened, with increases of 1·4–7·9% in Australia, 
Canada, and the Nordic countries, 0·0–1·3% in the three 
UK nations, and a small decrease (–1·6%) in Alberta. 
Survival in Denmark and the UK was lower than in other 
jurisdictions at all ages throughout 1995–2007, especially 
for those aged65 years and older (webappendix p 25).
Of 833 350 women with breast cancer, the mean age 
at diagnosis was 62·5 years (range 60·6–63·9; 
webappendix p 18). For 41 798 women (5·0%, 
range 1·8–11·0), breast cancer was not their ﬁ rst cancer 
(webappendix p 19). Death within 1 month of diagnosis 
was reported for 14 749 of 730 290 women (2·0%, 
range 0·3–2·5; webappendix p 20).
5-year survival in the UK and Denmark improved more 
than in the other four countries, so the international 
range in breast cancer survival has narrowed since 
1995–99 (table 2, ﬁ gure 2). This ﬁ nding might be a so-
called ceiling eﬀ ect, in that relative survival was more 
than 90% at 1 year and 82–88% at 5 years. 5-year and 
conditional 5-year estimates for 2005–07 in the UK and 
Denmark were still lower than in Australia, Canada, and 
Sweden, with Norway in an intermediate position. 
Survival in the UK was lower in all age groups during 
1995–99, and up to 20% lower than in Australian and 
Canadian jurisdictions for women aged 65 years or older 
at diagnosis (webappendix p 26).
Of 121 059 women with ovarian cancer, the mean 
age at diagnosis was 64·0 years (range 61·1–65·2; 
webappendix p 18). For 9437 women (7·8%, range 
6·1–13·5), ovarian cancer was not their ﬁ rst cancer 
(webappendix p 19). Death within 1 month of diagnosis 
was reported for 11 994 of 107 503 women (11·2%, 
range 6·3–12·9; webappendix p 20).
The geographical diﬀ erences in survival for ovarian 
cancer generally resembled those for colorectal cancer, 
with 1-year survival during 2005–07 generally lower in the 
UK and Denmark than in the other countries (table 2). 
However, geographical diﬀ erences in 1-year survival and 
the upward trend during 1995–2007 were much greater 
than for 5-year survival. Conditional 5-year survival for 
ovarian cancer in all three UK nations was higher than in 
New South Wales and Victoria, and close to the levels 
recorded in British Columbia and Ontario (table 2). 
Ovarian cancer survival at 1 year in Manitoba has 
ﬂ uctuated since the late 1990s and was 68% in 2005–07, 
15–20% lower than in other jurisdictions (table 2). The 
diﬀ erences were greater in women aged 55 years and 
older (webappendix p 26).
Discussion 
This study provides population-based survival estimates for 
2·4 million adults diagnosed with a cancer of the 
colorectum, lung, breast, or ovary up to 2007, in six 
countries (panel). Of the combined population of 
Figure 2: Age-standardised 1-year and 5-year relative survival trends 1995–2007, by cancer and country 
Data are for adults (15–99 years) diagnosed with colorectal, lung, breast, or ovarian cancer in 1995–99 and 2000–02 
(cohort approach), and short-term prediction of survival for those diagnosed in 2005–07 (period approach). Ovarian 
cancer data were not supplied by Sweden.
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123 million, 81% were covered by participating cancer 
registries. Data quality control and analyses were both done 
centrally with a common protocol, overseen by external 
experts. Data quality was high; less than 5% of eligible 
records (102 997/2 504 741) had to be excluded. Participating 
registries judged the survival estimates to be compatible 
with their own results, despite methodological diﬀ erences.
Survival improved for all four cancers in all six countries 
during 1995–2007, although there was some ﬂ uctuation 
within countries. Generally, Australia, Canada, and 
Sweden had the highest survival, with Norway somewhat 
lower. Survival was generally lowest in Denmark and the 
three UK nations. The largest gains were recorded for 
colorectal cancer, and the smallest for lung and ovarian 
cancer. Relative survival from breast cancer at 1 year 
exceeded 90% in all six countries; gains were smaller, 
and the international range in both 1-year and 5-year 
survival diminished. For cancers of the colorectum, lung, 
and ovary, survival at 1 year was generally lower in 
Denmark and the three UK nations, suggesting that late 
diagnosis is still a problem in both countries; however, 
1-year survival has increased more in Denmark since 
2000–02 than in the UK.
The incidence of invasive ovarian malignancy has been 
falling in all six countries since 1985 (webappendix p 28). 
The decrease since 2000 might be partly attributable to 
reclassiﬁ cation of some tumours of borderline malignancy 
from invasive, malignant behaviour (code 3) in ICD-O-2 
to uncertain behaviour (code 1) in ICD-O-3, but the 
protective eﬀ ect of oral contraception and increased 
diagnostic intensity, with earlier diagnosis and removal of 
borderline or premalignant lesions, could have contributed 
in the long term.25 However, survival analyses were 
restricted to invasive cancers, so this shift would tend to 
reduce overall survival in the tumours still classiﬁ ed as 
invasive, by removing up to 10% of tumours with good 
survival. Since survival actually rose in most jurisdictions, 
any eﬀ ect of this change seems to have been small.
We included both ﬁ rst and second (or higher-order) 
primary cancers in the analyses. The highest proportion 
of second and higher-order cancers was recorded in 
Manitoba, one of the oldest registries, and for three of 
the four cancers, the lowest proportion was in Northern 
Ireland, the newest registry (webappendix p 19). 
Sensitivity analyses will be done to show the eﬀ ect on 
survival estimates of including these patients. The eﬀ ect 
on 5-year survival is unlikely to exceed 1%.12
International diﬀ erences in survival cannot simply be 
attributed to poor-quality cancer registration, as has been 
suggested for breast cancer in the UK in particular.26 
Incidence, survival, and mortality trends are coherent for 
breast and other cancers (webappendix p 28), as they 
were when this issue was last discussed 10 years ago.27,28 
For example, although breast cancer mortality in the UK 
has decreased more quickly than in Sweden since 1985, it 
is still higher, whereas incidence has risen roughly in 
parallel, and the diﬀ erence in survival has decreased 
(compare ﬁ gure 2 and ﬁ gure 3). The Danish cancer 
registry is also highly regarded, with high-quality data, 
yet cancer survival patterns and trends in Denmark have 
been similar to those in the UK for several years, and the 
survival deﬁ cit with respect to other Nordic countries has 
motivated cancer strategy in Denmark, as in Britain.
Mortality-incidence ratios for breast cancer in 2000 are 
also somewhat higher in Denmark and the UK than in 
other countries (webappendix p 27). A large study has 
shown that breast cancer incidence recorded in-
dependently in primary care in the UK during 1990–96 
was very similar to incidence in the national cancer 
registry.29 Several studies have shown that access to 
radiotherapy varies widely in the UK; that manpower 
was low in the 1990s; and that elderly people and less 
aﬄ  uent groups were aﬀ ected by late diagnosis, treatment 
delays, and a survival deﬁ cit.30,31 Late-stage diagnosis 
accounts for much of the European variation in survival. 
High-resolution studies of hospital medical records 
(rather than cancer registry data) have shown that 
women with breast cancer in the UK were operated less 
often, have axillary dissection less often, and have fewer 
nodes sampled than do women in other countries.32 A 
study of more than 13 000 medical records has shown 
striking variation in breast cancer treatment in Europe 
in the late 1990s.33 Errors do arise in cancer registration, 
but the UK survival deﬁ cit is not explained by routine 
registration of recurrences as new diagnoses, or by 
failing to register long-term survivors. We will investigate 
this topic in a separate report.
Panel: Research in context
Previous evidence
The CONCORD1 and EUROCARE2 studies have shown wide 
international diﬀ erences in population-based cancer survival 
in patients diagnosed from the 1980s to 2002. The diﬀ erences 
represent many avoidable premature deaths, and they have 
helped to drive national cancer control strategies since 2000. 
This international study is the ﬁ rst phase in a programme to 
identify the reasons for persistent inequalities in survival, as 
the evidence base for health policy to reduce them.
Interpretation
We compared survival from cancers of the colorectum, lung, 
breast, and ovary in six countries for patients diagnosed 
between 1995 and 2007. The countries selected for study 
have similar wealth, universal health coverage, and high-
quality cancer registration. Survival has continued to improve 
for each cancer in all six countries, but generally remains 
higher in Australia, Canada, and Sweden, intermediate in 
Norway, and lower in Denmark and the UK. The patterns are 
consistent with later stage at diagnosis or diﬀ erences in 
treatment, particularly in Denmark and the UK and in older 
patients, and they prompt further examination of stage and 
treatment by the International Cancer Benchmarking 
Partnership to explain the diﬀ erences in survival.
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Other studies have suggested that the wide diﬀ erences 
in survival within Europe could be explained by large 
variation in diagnostic and surgical practice for colorectal 
cancer34 and in stage at diagnosis and treatment for breast 
cancer.32,35 Women older than 65 years with breast cancer 
in the late 1990s in England were less likely than younger 
women to receive triple assessment or guideline 
radiotherapy after conservative surgery.36 Chemotherapy 
and radiotherapy were later shown to increase long-term 
survival in early breast cancer. In Europe more generally, 
relative survival has improved more for women younger 
than 65 years at diagnosis than for older women; the 
widening deﬁ cit in survival in older women arises mainly 
in the ﬁ rst year after diagnosis, suggesting later diagnosis 
or less access to treatment.37 Survival from colorectal and 
breast cancers in England and Denmark is lower than in 
Australia, Canada, and most Nordic and western 
European countries.1,2,5,11 Improvements in colorectal 
cancer survival in England seem coherent with incidence 
and mortality trends.38 The lung cancer survival deﬁ cit in 
Denmark has been attributed to later stage at diagnosis 
and to the distribution of morphological types.39
The ﬁ ndings in this paper comprise a public health 
comparison of the survival of all patients with cancer in 
each jurisdiction, irrespective of stage at diagnosis or 
treatment, but after international diﬀ erences in non-
cancer mortality by age, sex, and calendar period are 
taken into account. Diﬀ erences in individual, health-
system, and clinical factors—such as public awareness 
of cancer, diagnostic delay, stage, comorbidity, and 
access to optimal treatment—are all potential 
explanations for the overall diﬀ erences in relative 
survival. We will examine later the extent to which 
diﬀ erences in stage at diagnosis, morphological type, 
and treatment for each patient can explain the survival 
disparities reported in this study, to provide evidence 
for strategy on how best to reduce the diﬀ erences. 
Obesity, physical activity, and other lifestyle variables 
might also aﬀ ect outcome.
Indicators of trend in incidence, survival, and mortality 
are all required for cancer control. Incidence rates refer 
to patients with cancer who are diagnosed in a speciﬁ c 
year. Almost all are registered, but those who are not 
might be a biased subset. Most cancers are registered 
from more than one data source, with pathological 
evidence of the diagnosis, but a small proportion are 
registered only from a death certiﬁ cate. Data quality 
control is extensive and well documented.13
Survival also refers to patients diagnosed in a speciﬁ c 
year. Relative survival is not subject to errors in 
certiﬁ cation of the cause of death, and is corrected for 
background mortality, but it is subject to lead-time bias. 
It reﬂ ects the overall outcome for all patients with cancer, 
not only those in clinical trials or those diagnosed early 
enough for treatment of curative intent. Relative survival 
is a measure of the overall eﬀ ectiveness of the entire 
health system, not only of treatment.
Mortality is a function of both incidence and survival. 
Mortality rates refer to the number of people who die in a 
speciﬁ c year. Lung cancer survival has been low for many 
years, so mortality trends are largely parallel with 
incidence trends (webappendix p 28). By contrast, more 
than 40% of women who die of breast cancer in a speciﬁ c 
year will have been diagnosed at least 5 years previously, 
so trends in mortality provide a delayed and imprecise 
picture of any trends in survival. It is not possible to draw 
conclusions about trends in survival from trends in 
mortality alone. Unlike relative survival, mortality rates 
are subject to errors in certiﬁ cation of the cause of death, 
particularly in elderly patients. Autopsies are infrequent, 
and quality control of death certiﬁ cate data is far more 
limited than that of incidence data. Mortality data are 
nevertheless almost complete, and long time series are 
available. They are an invaluable public health resource.
The consistency of incidence, survival, and mortality 
trends in Europe has led other investigators to conclude 
that joint interpretation of these indicators is the best 
guide to policy for prevention, screening, treatment, 
and the organisation of health-care systems.40 We agree 
with this conclusion. Primary prevention to reduce 
Figure 3: 3-year moving-average world-standardised incidence and mortality rates per 100 000 population per 
year, 1985–2005, by country, for breast cancer in women and colorectal cancer in men and women combined
Incidence for Canada excludes Quebec; colorectal cancer includes cancers of the anus and anal canal; lung cancer 
includes cancers of the trachea. Incidence data labelled UK are for England only; mortality data labelled UK are for 
England and Wales only.
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incidence remains the best long-term strategy to reduce 
the cancer burden; incidence trends will thus remain a 
crucial policy guide. Until the causes of cancer are more 
fully understood, however, and eﬀ ective strategies for 
prevention are fully implemented, millions of people 
will continue to be diagnosed with cancer every year. 
Therefore, for policy makers who have to deliver eﬀ ective 
care to these patients, population-based survival will 
also remain a key indicator of progress. Even small 
improvements in survival from common cancers can 
prevent large numbers of premature deaths.41 Cancer 
registration systems should be supported to improve 
the quality and completeness of their data. Systematic 
collection of data for comorbidity and other possible 
determinants of survival should also be introduced. 
Clinicians should be encouraged to record the data that 
are needed for population-based comparisons more 
systematically. Information systems should be improved 
to help with recording of these data.
Additional indicators for routine monitoring of 
progress in cancer control are needed. For example, 
diﬀ erences in relative survival between two countries or 
regions can be expressed as the number of cancer-related 
(excess) deaths in patients with cancer in one country 
that would be avoidable within, say, 5 years of diagnosis 
if relative survival were as high as in the other country.6 A 
decrease in the number of such avoidable, premature 
deaths can provide a useful comparative index of 
progress; it incorporates the relative eﬀ ectiveness of both 
health systems, remains applicable when survival is 
improving in both countries, and might be more readily 
understood by the general public.
Survival trends can help both in the formulation of 
strategies for cancer control and in the assessment 
of their eﬀ ectiveness. The International Cancer 
Benchmarking Partnership aims to provide robust and 
timely comparison of trends in cancer survival between 
countries or regions with good population-based data. 
Later phases of this partnership will explore the eﬀ ect on 
international survival disparities of diﬀ erences in public 
awareness and beliefs about cancer, duration of 
symptoms, diagnosis in primary and secondary care, 
comorbidity, and access to treatment. The goal is to 
identify remediable causes of survival deﬁ cits, to inform 
the development of new cancer control policy in 
participating countries.
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